The Case for a Public Benefit Biopharma Industry

The for-profit biopharma industry is incentivized to maximize profits, increasing prices and decreasing patient access to biologics. Moreover, they are disincentivized to prioritize products like vaccines and antibiotics that historically have lower profit margins. A new article in STAT News argues that a push towards a public benefit biopharma industry could help address this situation and support innovation.

According to the authors, “We propose a systematic solution to the financing conundrum. It will serve as a model that can unlock billions of already invested capital, both dollars and intellectual. Companies built on this model can provide returns on investment for investors that are risk-adjusted with an old-fashioned business plan that requires them to be cost and time efficient with the customers’ interests in focus: good medicine at sustainable cost.”

To read more, click here.

(Source: October 13^th, 2022)